The nitroimidazole prodrug Evofosfamide (TH-302) [493,494,495,496] releases alkylating agents upon reductive cleavage while concomitantly producing cytotoxic free radicals, synergistically exacerbating local oxidative damage
Study medication quality and tolerability Independent analysis of three separate samples compounded to contain 200 mg/ml demonstrated the product potency to be 190 mg/ml (95%) upon receipt, and potency reduced to 144 mg/ml (72%) at 4 weeks in one sample, and 161 mg/ml (80.5%) at 6 weeks in a separate batch
NAD-boosting increased 4-6 fold the blood NAD + depending on individual, pointing to need of personalized dose adjustment in treatment trials
[13] [15] Common side effects include local reactions at the injection site, such as pain, swelling, or erythema
Within the type category, 97% purity is expected to witness higher growth over the forecast period
It does smell nice but the problem is that it oxidizes on air exposure and the resulting stuff is not good for the skin
